Healthcare
27/100
27/100Is IBRX-ImmunityBio, a buy?
Tuesday 4 August 2026
Why now: The stock is well below prior resistance and has weak relative strength, but the next 6–12 months include meaningful regulatory and commercial execution checkpoints that can change the long-term narrative if they go well. This is a “business proof” moment: adoption, financing discipline, and regulatory follow-through matter more than social hype.
Upside: Wall Street’s published target implies about 82% upside versus the prior close, reflecting the view that ANKTIVA adoption and label expansion could re-rate the revenue base. That upside is highly dependent on execution and on reducing near-term funding pressure.
Risks: Cash runway is very short relative to free cash flow burn, making dilution and financing terms a central risk. Regulatory and compliance risk is elevated after FDA promotional correspondence, which can slow momentum if missteps continue.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free — no credit card needed.
Scorecard
Read:Strong metricsSolid metricsSelectiveCautionUnfavourableN/A
| Scorecard | 27/100 | |
|---|---|---|
| Company Detail | IBRX - ImmunityBio, Inc. | |
| Price as at 3 August 2026 | $7.15 | |
| Market cap | $7.5B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 4/20 | |
| Rev/EPS Momentum /20 | 0/20 | |
| Business Quality /15 | 8/15 | |
| Balance Sheet /15 | 2/15 | |
| Valuation /10 | 2/10 | |
| Industry Relative Strength /10 | 1/10 | |
| Macro / Sector Tailwind /10 | 10/10 | |
| Growth | ||
| Cash runway | 0.25 yr | |
| Revenue YoY | +668.3% | |
| EPS YoY | +38.7% | |
| FCF YoY | +22.4% | |
| Gross margin | 99.3% | |
| Valuation & Trend | ||
| Trailing P/E | neg | |
| Forward P/E | — | |
| RSI (14d) | 43 | |
| vs 50d SMA | -6.7% | |
| Support cushion | −5.0% | |
| Sentiment | ||
| Wall Street verdict | Disagrees | |
| News tone | Positive | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Tuesday 4 August 2026
What they do
ImmunityBio is a commercial-stage biotechnology company focused on cancer immunotherapy. Its current revenue base is tied to ANKTIVA, and the investment story depends on expanding use, securing additional approvals, and executing a safe, compliant commercial launch.
Leadership
Richard Gerald AdcockCEO
Richard Gerald Adcock serves as President, Chief Executive Officer and Director of ImmunityBio, Inc.
David C. SachsCFO
David C.
Customers & notable contracts
Receiver of capital expenditure: No — This is a drug developer and commercial-stage biotech; it does not typically receive customer capital expenditure in the way industrial or infrastructure suppliers do.
Main customers
- Urology clinics and hospital systems treating bladder cancer (Potential customers are care sites that administer bladder cancer therapies and follow guideline-driven treatment pathways.)
- Oncology practices and cancer centers (A broader immunotherapy footprint would rely on oncology networks if additional indications expand beyond bladder cancer.)
Notable contracts
- n/a (No specific customer contracts were verified in public sources for this report.)
Summary thesis
- ImmunityBio has a real, marketed immunotherapy product, and the long-term upside is tied to expanding clinical utility and winning additional approvals that broaden the treatable population.
- The opportunity is real, but the company currently looks like a high-volatility ownership candidate because it must fund a commercial build-out while still burning substantial cash.
- The most important question over the next year is whether execution can convert approvals and international authorizations into durable revenue growth without repeated dilution.
Wall Street alignment
Wall Street: Wall Street disagrees (2/4 negative)
Analyst consensus
Buy (2.00, 5 analysts) · +82% upside
Institutional ownership
18% institutions, insiders 62.5%
Short interest
34.6% of float short · 10.2 d-to-cover
Smart money tape
+1 net (acc 1 / dist 0, last 26d)
Recent news
News Positive · last 7d
Show 1 headline from the last 7d
2026-07-29Regulatory+supportive
ImmunityBio says United Arab Emirates grants marketing authorization for ANKTIVA in bladder and lung cancer indications ↗ · Business Wire
ImmunityBio said the United Arab Emirates granted marketing authorization for ANKTIVA for Bacillus Calmette-Guérin unresponsive non muscle invasive bladder cancer and for metastatic non small cell lung cancer in combination with immune checkpoint inhibitors. The decision expands the company’s international commercial footprint and supports its thesis around broader global adoption of ANKTIVA.
Dividends
Pays no regular dividend.
Technicals
Price
$7.15
RSI (14d)
43.5
50d SMA
$7.66
200d SMA
$5.94
vs 50d SMA
-6.7%
vs 200d SMA
+20.4%
Support (swing low)
$6.80 −5.0%
40-day high (R)
$9.60 +34.3%
Next swing high (swing high)
$8.14 +13.8%
Close as of 2026-08-03.
Score breakdown
Scores 27 out of 100 — a mixed overall grade. Sector fit scored highest. Business quality was fair but not a standout driver. Chart setup and valuation weighed on the total. Score is capped by the weak technical setup, very weak cash position versus ongoing cash burn, and elevated dilution risk. Even with a real approved product, the balance-sheet risk is large enough to limit long-term ownership quality at this time. Mechanical cap: latest annual net income ≤ 0 — Balance Sheet ≤ 3/15, Rev/EPS ≤ 0/20, overall ≤ 50/100.
Component scores are on the scorecard above.
Momentum evidence
- At the most recent print the stock is around $7.16 in premarket trading, essentially flat versus the prior close, but the broader tape is weak.
- The last completed daily bar shows the stock below its 50-day average, far below prior resistance around $9.60, and with poor industry-relative strength, which signals the market is not rewarding the story right now despite a rising 200-day average.
Fundamental evidence
- The company is still in a heavy investment phase: latest annual revenue is $113.29M with net income of about -$351.40M and free cash flow of about -$308.78M.
- Cash is about $75.67M with a computed cash runway of roughly 0.25 years, and share count is up about 140% over five years, which makes dilution risk a practical near-term issue rather than a theoretical one.
- Profitability and efficiency metrics are weak (negative returns on invested capital and assets), and valuation is demanding for the current revenue scale (EV/Sales is about 44.7).
- On the positive side, the company has an approved product platform and is actively pursuing label expansion, but the funding and compliance profile must improve for this to look like a durable long-term compounder rather than a recurring capital-raise story.
- Chart note — net income: Net income was -$351M in 2025.
- The pick assumes this is transitional and that the setup plus business quality still merit inclusion — verify the loss driver in filings before sizing up.
Cash runway: 0.25 yr ($76M cash ÷ $309M/yr burn, latest fiscal year).
Valuation view
Valuation looks priced for major growth despite current losses: EV/Sales is about 44.7 on the latest annual revenue base, and free cash flow is deeply negative, so traditional earnings or cash flow multiples are not supportive. For this to look reasonable on a 1+ year horizon, the company needs fast revenue scaling and a visible path to lower cash burn, because multiple compression risk is high if growth slows or funding costs rise.
Macro tailwind
Healthcare demand is resilient, and immunotherapy remains a priority area, but markets are still penalizing companies that need frequent financing. The macro tailwind helps the category, yet it does not solve ImmunityBio’s near-term funding and execution requirements.
What to watch
Upcoming (1–6 months)
- Regulatory milestone on the ANKTIVA plus BCG supplemental application for papillary disease, with a stated FDA action date of January 6, 2027.
Ongoing
- Quarterly revenue progression and cash burn trend, including any financing announcements that change dilution risk.
Long-term case
The multi-year case is that ANKTIVA becomes a durable immunotherapy platform with growing use in bladder cancer and potential expansion into additional settings, turning early commercial traction into a meaningfully larger revenue base. If that happens while operating losses narrow and funding becomes less dilutive, the stock could re-rate substantially. If adoption is slower than expected or the company repeatedly needs equity funding, long-term returns can be capped even if the science is promising.
Risks & invalidation
Risks
- Near-term financing risk: with limited cash runway and negative free cash flow, shareholder dilution or expensive capital could dominate outcomes.
- Regulatory and compliance risk: further promotional or manufacturing-related issues could slow uptake, restrict messaging, or delay expansion plans.
Breaks the thesis
- If the stock cannot regain and hold above its 50-day moving average and later cannot break and hold above $9.60 resistance, the market is signaling it does not believe in near-term execution, which undermines the investment case.
Bottom line
ImmunityBio is a commercial-stage biotech with a real immunotherapy product, but it currently looks more like an execution-and-financing story than a steady long-term compounder. The swing factor over the next year is whether ANKTIVA adoption and label-expansion progress can outpace cash burn and reduce dilution risk while the company stays on the right side of FDA promotional compliance. Until those pieces improve, the business risk is not the science alone, but the balance sheet and execution discipline.